Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.

Lin L, Xu X, Yu Y, Ye H, He X, Chen S, Chen X, Shao Z, Chen P

The Journal of dermatological treatment24 Sept 2020Cited by 58 (Europe PMC)

PMID32962477DOI10.1080/09546634.2020.1826392PepBankPUB-32962477

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with psoriasis and type 2 diabetes, the change in PASI from baseline differed significantly between the liraglutide group and the control group.
In plain wordsIn adults with psoriasis and type 2 diabetes, psoriasis severity scores changed more with liraglutide than in the control group.
Peptide
Liraglutide
Outcome
DecreasePASI change versus control
Study
n = 25
Comparator
Control group
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Compared to week 12, the change in the baseline value of PASI and DLQI in the treatment group showed a significant difference compared with the control group (p < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
The skin lesions in psoriasis patients with type 2 diabetes were significantly improved after treatment with liraglutide
Summary · context
A total of 25 psoriasis patients with type 2 diabetes were randomized 1: 1 divided into the control group (n = 13) or liraglutide group (n = 12) for 12 weeks.
Report a problemFND-3296247702
02HumanRandomized controlled trialEfficacy outcome
In adults with psoriasis and type 2 diabetes, the change in DLQI from baseline differed significantly between the liraglutide group and the control group.
In plain wordsIn adults with psoriasis and type 2 diabetes, quality-of-life scores changed more with liraglutide than in the control group.
Peptide
Liraglutide
Outcome
DecreaseDLQI change versus control
Study
n = 25
Comparator
Control group
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
Compared to week 12, the change in the baseline value of PASI and DLQI in the treatment group showed a significant difference compared with the control group (p < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
After 12 weeks of treatment, the mean DLQI of the treatment group decreased from 22.00 ± 5.85 to 3.82 ± 3.60 (p < .05).
Summary · context
A total of 25 psoriasis patients with type 2 diabetes were randomized 1: 1 divided into the control group (n = 13) or liraglutide group (n = 12) for 12 weeks.
Report a problemFND-3296247703
03HumanRandomized controlled trialSafety outcome
In adults with psoriasis and type 2 diabetes, no serious adverse events occurred.
In plain wordsIn adults with psoriasis and type 2 diabetes treated for 12 weeks, no serious side effects occurred.
Peptide
Liraglutide
Outcome
No significant changeSerious adverse events
Study
n = 25
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
No serious adverse events occurred.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 25 psoriasis patients with type 2 diabetes were randomized 1: 1 divided into the control group (n = 13) or liraglutide group (n = 12) for 12 weeks.
Report a problemFND-3296247708
04HumanRandomized controlled trialEfficacy outcome
In adults with psoriasis and type 2 diabetes, mean DLQI in the liraglutide group fell from 22.00 to 3.82 after 12 weeks.
In plain wordsIn adults with psoriasis and type 2 diabetes, quality-of-life scores on liraglutide improved markedly over 12 weeks.
Peptide
Liraglutide
Outcome
DecreaseDLQI change from baseline
Study
n = 12
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
Mean DLQI at baseline
22 score
liraglutide group
Mean DLQI at week 12
3.82 score
liraglutide group
Source sentences
Summary
After 12 weeks of treatment, the mean DLQI of the treatment group decreased from 22.00 ± 5.85 to 3.82 ± 3.60 (p < .05).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 25 psoriasis patients with type 2 diabetes were randomized 1: 1 divided into the control group (n = 13) or liraglutide group (n = 12) for 12 weeks.
Report a problemFND-3296247701
05HumanRandomized controlled trialEfficacy outcome
In adults with psoriasis and type 2 diabetes, pathological changes in psoriasis skin were improved in the liraglutide group.
In plain wordsIn adults with psoriasis and type 2 diabetes, skin biopsies of psoriasis looked better in the liraglutide group.
Peptide
Liraglutide
Outcome
DecreaseHistopathology of psoriasis skin
Study
n = 12
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
The pathological changes of psoriasis skin
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 25 psoriasis patients with type 2 diabetes were randomized 1: 1 divided into the control group (n = 13) or liraglutide group (n = 12) for 12 weeks.
Report a problemFND-3296247704
06HumanRandomized controlled trialEfficacy outcome
In adults with psoriasis and type 2 diabetes, IL-17 expression in psoriasis skin was improved in the liraglutide group.
In plain wordsIn adults with psoriasis and type 2 diabetes, skin levels of the inflammation signal IL-17 improved in the liraglutide group.
Peptide
Liraglutide
Outcome
DecreaseIL-17 expression in psoriasis skin
Study
n = 12
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
The pathological changes of psoriasis skin and the expression of IL-17, IL-23, TNF-α in the psoriasis skin were improved in the treatment group.
2 context sentences(design, population, supporting numbers)
Summary · context
which may be related to the inhibition of the expression of inflammatory factors such as IL-23, IL-17, and TNF-α.
Summary · context
A total of 25 psoriasis patients with type 2 diabetes were randomized 1: 1 divided into the control group (n = 13) or liraglutide group (n = 12) for 12 weeks.
Report a problemFND-3296247705
07HumanRandomized controlled trialEfficacy outcome
In adults with psoriasis and type 2 diabetes, IL-23 expression in psoriasis skin was improved in the liraglutide group.
In plain wordsIn adults with psoriasis and type 2 diabetes, skin levels of the inflammation signal IL-23 improved in the liraglutide group.
Peptide
Liraglutide
Outcome
DecreaseIL-23 expression in psoriasis skin
Study
n = 12
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
The pathological changes of psoriasis skin and the expression of IL-17, IL-23, TNF-α in the psoriasis skin were improved in the treatment group.
2 context sentences(design, population, supporting numbers)
Summary · context
which may be related to the inhibition of the expression of inflammatory factors such as IL-23, IL-17, and TNF-α.
Summary · context
A total of 25 psoriasis patients with type 2 diabetes were randomized 1: 1 divided into the control group (n = 13) or liraglutide group (n = 12) for 12 weeks.
Report a problemFND-3296247706
08HumanRandomized controlled trialEfficacy outcome
In adults with psoriasis and type 2 diabetes, TNF-α expression in psoriasis skin was improved in the liraglutide group.
In plain wordsIn adults with psoriasis and type 2 diabetes, skin levels of the inflammation signal TNF-α improved in the liraglutide group.
Peptide
Liraglutide
Outcome
DecreaseTNF-α expression in psoriasis skin
Study
n = 12
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Source sentences
Summary
The pathological changes of psoriasis skin and the expression of IL-17, IL-23, TNF-α in the psoriasis skin were improved in the treatment group.
2 context sentences(design, population, supporting numbers)
Summary · context
which may be related to the inhibition of the expression of inflammatory factors such as IL-23, IL-17, and TNF-α.
Summary · context
A total of 25 psoriasis patients with type 2 diabetes were randomized 1: 1 divided into the control group (n = 13) or liraglutide group (n = 12) for 12 weeks.
Report a problemFND-3296247707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.